Oral Drug Delivery Systems: Continuous-Release Systems
Transdermal Drug Delivery Systems
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Noncompartmental Analysis: Mean Transit, Absorption and Dissolution Time
Modified-Release Drug Delivery Systems: Influencing Factors
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: May 3, 2026

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
Published on: May 19, 2020
Joseph V Pergolizzi1, Rami Ben-Joseph, Chun-Lan Chang
1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.; Temple University School of Medicine, Philadelphia, Pennsylvania, U.S.A.; Naples Anesthesia and Pain Associates, Naples, Florida, U.S.A.
Prior use of opioids and adjuvant analgesics, along with dose adjustments, significantly increase buprenorphine transdermal system (BTDS) persistence. This suggests personalized treatment strategies improve patient adherence to chronic pain therapy.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: